A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas - Concepedia

Concepedia

Publication | Open Access

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas

DOI Full Paper Access

71

Citations

20

References

2016

Year

Walter Fiedler, S. DeDosso, Sara Cresta, Jens Weidmann, Anna Tessari, Marc Salzberg, B. Dietrich, Harald Baumeister, Steffen Goletz, Luca Gianni,

European Journal of Cancer

Abstract

PankoMab-GEX is safe, well tolerated, and showed promising anti-tumour activity in advanced disease. A phase IIb study is ongoing evaluating the efficacy of PankoMab-GEX as a maintenance therapy in advanced ovarian cancer.

References

	Year	Citations

Page 1